Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 24, 2026
Grail, Inc. (GRAL)
A forensic read on Grail, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
4.1
Distress distance
Clean
Earnings quality
3
Forensic signals
-8.3
P / E (ttm)
-15.8%
ROE
$4.8B
Market cap
0.00%
Dividend yield
17.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Grail, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 4.1, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+15.2%/yr
FY2024–FY2025
Share-count dilution.Diluted share count changed +15% over the last 1 year to FY2025 (+15.2%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~15.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~13%.
40% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 40% of revenue in FY2025 — about $1.59 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 15.2% a year, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
$889M
FY2024–FY2024
Goodwill impairments.Took $889M of goodwill writedowns across 1 year (FY2024 ($889M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$147.2M
Revenue Growth YoY+17.2%
Net Margin-277.5%
Free Cash Flow-$299.9M
Return on Equity-15.8%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Grail, Inc.'s actual 10-K/10-Q/8-K filings?